AstraZeneca Reports Five-Year PROfound Data for Lynparza in BRCA-Mutated Prostate Cancer

AstraZeneca today presented five-year follow-up data from the Phase 3 PROfound trial evaluating Lynparza (olaparib) versus enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations. The data showed that the overall survival benefit of Lynparza was maintained over five years of follow-up.